Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
GETUG-AFU22 trial: what clinicians have said so far
Comparison of HT Concomitant With RT vs RT Alone in Patients With a Detectable PSA After Prostatectomy
- NCT01994239 ↗
- Active, not recruiting
- UNICANCER
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on GETUG-AFU22 (degarelix in prostate adenocarcinoma with detectable PSA after prostatectomy) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on GETUG-AFU22 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 6 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Multicenter Randomised Phase II Study Comparing the Efficiency of a HT Concomitant With RT vs RT Alone in the Salvage of Patients With a Detectable PSA After Prostatectomy
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Adenocarcinoma of Prostate
- Interventions
- Degarelix; Pelvic Radiotherapy
- Arms
- Radiation · Active comparator
- Radiation and Degarelix · Experimental
- Enrollment
- 120 (estimated)
- Primary outcomes
- The efficacy of the combination of hormonal therapy by degarelix and radiotherapy on event-free survival
- Sponsor
- UNICANCER with Ferring Pharmaceuticals
- Start
- Dec 2012
- Primary completion
- Mar 2022
- Results posted
- No
- Registry record
- NCT01994239 · updated Dec 16, 2024